Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zoetis Inc Cl A (ZTS)

Zoetis Inc Cl A (ZTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

What to Expect From Zoetis' Next Quarterly Earnings Report

Valued at a market cap of $55.2 billion, Zoetis Inc. (ZTS) discovers, develops, manufactures, and commercializes animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products. The Parsippany, New Jersey-based company is scheduled to announce its fiscal Q4 earnings for 2025 before the market opens on Thursday, Feb. 12. 

Before this event, analysts expect this animal healthcare company to report a profit of $1.40 per share, in line with the year-ago quarter. The company has topped Wall Street’s earnings estimates in each of the last four quarters. In Q3, its EPS of $1.70 surpassed the consensus estimates...

Fundamentals

See More
  • Market Capitalization, $K 55,210,020
  • Shares Outstanding, K 440,693
  • Annual Sales, $ 9,256 M
  • Annual Income, $ 2,486 M
  • EBIT $ 3,462 M
  • EBITDA $ 3,959 M
  • 60-Month Beta 0.97
  • Price/Sales 5.96
  • Price/Cash Flow 17.80
  • Price/Book 10.33

Options Overview Details

View History
  • Implied Volatility 38.25% (-0.97%)
  • Historical Volatility 20.03%
  • IV Percentile 94%
  • IV Rank 66.61%
  • IV High 46.55% on 04/07/25
  • IV Low 21.70% on 02/20/25
  • Expected Move (DTE 35) 9.84 (7.90%)
  • Put/Call Vol Ratio 2.29
  • Today's Volume 8,404
  • Volume Avg (30-Day) 2,325
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 73,597
  • Open Int (30-Day) 71,841
  • Expected Range 114.81 to 134.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.40
  • Number of Estimates 10
  • High Estimate 1.41
  • Low Estimate 1.38
  • Prior Year 1.40
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
121.12 +2.91%
on 12/22/25
131.13 -4.94%
on 01/06/26
+1.42 (+1.15%)
since 12/16/25
3-Month
115.25 +8.16%
on 11/19/25
148.30 -15.95%
on 10/22/25
-18.61 (-12.99%)
since 10/16/25
52-Week
115.25 +8.16%
on 11/19/25
177.40 -29.74%
on 02/06/25
-44.72 (-26.40%)
since 01/16/25

Most Recent Stories

More News
What to Expect From Zoetis' Next Quarterly Earnings Report

Zoetis is expected to announce its fiscal fourth-quarter earnings next month, and analysts project earnings in line with the year-ago quarter.

XLV : 155.74 (-0.78%)
$SPX : 6,940.01 (-0.06%)
ZTS : 124.65 (-0.50%)
1 Profitable Stock with Solid Fundamentals and 2 We Brush Off

1 Profitable Stock with Solid Fundamentals and 2 We Brush Off

CACC : 472.03 (-0.31%)
ARW : 118.20 (-0.38%)
ZTS : 124.65 (-0.50%)
2 Safe-and-Steady Stocks with Competitive Advantages and 1 We Turn Down

2 Safe-and-Steady Stocks with Competitive Advantages and 1 We Turn Down

ZTS : 124.65 (-0.50%)
NMIH : 38.01 (+1.04%)
LOPE : 178.29 (-0.95%)
Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2025 Financial Results

Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 12, 2026. Chief Executive Officer Kristin Peck and Executive Vice President...

ZTS : 124.65 (-0.50%)
Zoetis to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Zoetis Inc. (NYSE:ZTS) will participate in the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph,...

ZTS : 124.65 (-0.50%)
Zoetis Announces Pricing of $1.75 Billion Convertible Senior Notes Offering

Substantially All of Net Proceeds Expected to Be Used to Repurchase Approximately $1.6 Billion of Common Stock and for Capped Call Transactions

ZTS : 124.65 (-0.50%)
Zoetis Announces Proposed $1.75 Billion Convertible Senior Notes Offering

Substantially All Net Proceeds Expected to Be Used to Repurchase Common Stock and for Capped Call Transactions

ZTS : 124.65 (-0.50%)
Zoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment Increase

The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025....

ZTS : 124.65 (-0.50%)
3 Cash-Producing Stocks with Exciting Potential

3 Cash-Producing Stocks with Exciting Potential

LRCX : 222.96 (+2.52%)
ZTS : 124.65 (-0.50%)
LYTS : 19.85 (-0.10%)
Zoetis Receives Health Canada Approval for Portelaâ„¢(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats

Zoetis Inc. today announced that Health Canada has approved Portela â„¢ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed...

ZTS : 124.65 (-0.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Zoetis Inc. is a leader in the animal health space with a focus on both livestock and companion animals in seven major product categories: vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. Zoetis has a diversified...

See More

Key Turning Points

3rd Resistance Point 128.31
2nd Resistance Point 127.10
1st Resistance Point 125.88
Last Price 124.65
1st Support Level 123.45
2nd Support Level 122.24
3rd Support Level 121.02

See More

52-Week High 177.40
Fibonacci 61.8% 153.66
Fibonacci 50% 146.32
Fibonacci 38.2% 138.99
Last Price 124.65
52-Week Low 115.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar